Authors: Craig A Erickson Jennifer E Mullett Christopher J McDougle
Publish Date: 2009/07/16
Volume: 39, Issue: 12, Pages: 1629-1635
Abstract
Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome FXS The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS Medical records describing openlabel treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed Six patients received memantine over a mean 347 weeks of treatment Four of 6 67 patients showed global clinical benefit on ratings with the CGII Symptom specific rating scales however showed no statistically significant improvement Two patient developed treatmentlimiting irritability on memantine Memantine was modestly effective in several patients with FXS Further systematic study is warrantedThis work is supported in part by The Division of Disability Rehabilitative Services Indiana Family and Social Services Administration Drs Erickson McDougle National Institute of Health grant K12 UL1 RR025761 Indiana University Clinical and Translational Sciences Institute Career Development Award Dr Erickson and NIMH grant R01 MH072964 Dr McDougle
Keywords: